they please the court the question before the court when one looks at the entire district court opinion in this case is what could be stronger objective indicia of non obviousness than the fact that the authors of virtually all of the pertinent prior art told us that we could not do what we accomplished doing and in fact had tried and failed themselves have the district court conducted the appropriate legal analysis rather than conducting a hindsight analysis coming to its opinion on obviousness and then and only then turning to the objective indicia and shifting the burden to the plane to have the district court not done that we would have had a different result well you've got a lot packed into the suit if you just made firstly the district court did go through a detailed analysis did he not of all of the prior art detailing disagree with his analysis but he did the analysis he did the analysis of the objective indicia only after coming to the conclusion that the claims were obvious and then the analysis wasn't so much a critique of the objective and just yet he accepted that indeed it showed what it showed but each time he said that it was not enough to overcome the court's finding of obviousness and what this court said less than two months ago in  advocated that we have the burden of persuasion of demonstrating non obviousness and yet if we look at what the district court that at the very end of the district court summary of its obvious forty nine the district court says as follows while some persons of ordinary skill in the art believed it would be challenging to develop a once a day trust in formulation the plaintiffs meaning us have not demonstrated that there was a widespread belief that the claims invention what's possible or that the challenge is to trust in what insurmountable such that development of the claimed invention was on an unexpected in light of the persuasion rather than production it was our burden to demonstrate that there was a widespread belief that the claimed invention was possible or that the challenges atrocity and were insurmountable first of all we don't have the s and then step that bar so high that it reports be impossible to do since clearly we can't demonstrate that the claims invention was impossible we succeeded and clearly we can't demonstrate that the hurdles were insurmountable we surmounted them so that the but the district court made clear i think in page fourteen what the legal standard was outlining the four factors under graham and then stating a burden to fight with the district at that age fourteen when we get to pages forty six forty seven forty eight and forty nine the burden had been shifted to the plaintiffs to demonstrate that there was non obviousness and what happened in this is unfortunately it's difficult for a district court in an extended release case because there is no doubt that the court is going to find in the prior art and immediate release version the court is going to find in the prior art the technology to enable taking an immediate release molecule and putting it into an extended release form form it that's all going to be there and there's even the technology to release have a at least part of the release in the colon however what all the poster that the person skilled in the art would have expected from trusty i'm a quaternary ammonium compounds and let me just digress for one minute no dispute the trojan is a questionnaire a million compound notices that means it's permanently positively charge in this instance because of the different properties of the color they would have predicted this sort of value meaning the negligible colonic absorption that they would have put this aside they would have spent no more than one minute of looking at it this was taken out of context by both the district court and opposing counsel in trying to say that the our expert dismissed or you know our experts simply said schroeder would be put aside because it simply caught with everyone still in the art knew the quaternary ammonium compounds are not absorbed in the tories war produced manufactured and sold by mad out the very company who did the schroeder poster and by the way the another error by the district court was the district court dismissed the show to posters never however what evidence that was considered by the district court differ court is obviously looking at all the evidence and weighing in balancing and coming to a conclusion in the but what the district court did with ignore the fact that th true we did it and so it's not hearsay we did not offer it for the truth of the matter asserted we offered it to show skepticism by others and the fact that matter out that it could not be done and we overturn that just isn't an actually did it more importantly tho and the court or the proposition that men have never had once the program cited some testimony of dr standage but cited out of context if we look at the testimony of dr standards at eight ten to thirty two and two thirty three dr standage talks question about the hearsay dr standage indeed testified to what he told by now and what he was told by bale but in addition to that we have the contemporaneous documents of madoff we have the schroeder poster we have the peer review publication absorbtion to say they weren't interesting in partnering with us now again this is contemporaneous documents not something that experts are saying ten years later and what the court stressed in recycle ben supreme and reiterate particulates formulations that are designed to target release in the g i tract twenty five years it's not done where is there any analysis of the effect of that lengthy period of time on a showing of non obviousness the question your honor is what can we take from that failure and we have to look at the state of it all it was so obvious why did it take the brightest minds in the  pharmaceutical world thirty years to do it there's absolutely no evidence your honor that there was meaningful motivation or a good cry or there's no motivation you've got you've got for one thing you've got side effects if you're taken two pills a day you're doubling the side effects if you can cut the side effects by a half that's motivation i didn't hear any discussion of that by the way in the record i did that first of all your honor there's no having that the side effect that testimony which that's not my point your honor if you double the dose of an immediate release go through twenty to forty or go from forty to eighty of course you increase the side of so there is an automatic motivation to cut from two pills a day to want that is not the way it goes you're not was a three or four day i'm sorry three or four times a day product as well terry was twice a day changeover to those driving the commercial motivation two thousand and two and this solution for the relatively person of ordinary skill in the art make of the poster and would that poster the motivation for remove a reasonable expectation of six x and the if there was there was other evidence was relating to that's the evidence we have here we don't have evidence that matt ousts took a license back to a patent to practice something we wanted nor do we have evidence that mad doubts the company was skeptical and as to the truth of the matter asserted point i agree that a person state of mind just hearsay exception so if a person says i'm skeptical because i don't believe it can be done that is that person's state of mind that's not hearsay and that was what was offered a trial the secondary considerations and more to the point your honor the key secondary consideration here was that way outside in the infringement context we don't do crime a facial and then you've got to prove it the other way  zine you secondary considerations are part of the equation beginnings and of course and they we don't do the well case they proved their side of the story now you've got a rebuttal and that's not no one would want to cut from two pills to one the first day that's not correct your honor so two pills a day is not so for example rovner says that oxy if you try men which is three or four times a day had serious compliance problems but then he says it's whole parenting which is twice a day does not have compliance problems because of that and saying that tor in germany was a twice a day product so yes going from twice a day to once a day is not make got to reduce side effects yet got to improve convenience to the to the customer got to improve in every way if it's possible the point is nobody thought it was possible so you didn't spend any time there until some people started to do it in other areas in the ninety nine five era and then people started to look at your own about looking at something and saying nobody motivation was always there i don't agree just added your honor you know you're just saying that nobody figured it out that it was possible till later and then you started to research it evidence that you that others started to research it more enthusiastically in the one nine hundred ninety s doesn't suggest that there wasn't a motivation for improvement learning that's not incorrect but what we do have your honor is a difference between saying nobody did it therefore it can't have been obvious that's the anticipation whenever we're talking about obvious nobody actually did it before otherwise this would be an anticipation case and the fact that a company we don't know what mass is commercial  imperatives are we don't know if this was a good drug for them we don't know what the market was like in germany we don't know if they had the budget to do it we don't know if they could switch to a different kind of formulation work in general we just don't know and dr fewer is really what we're talking office who examined all of the same information granted this patent you had to overcome by clear and convincing evidence without improperly shifting the burden and their least three things out of the didn't happen well again your honor the district court analysis of skepticism which was their key secondary consideration was primarily addressed by us as the first three grand factors because what we have here is the argument based on multiple particulates formulations targeted at the g i tract far before the court you picked out these but that that was going on long before that's not just the way you get one extended release formulat this word mr kramer have four minutes to divide between dissolution test so we have to be clear what this what this model is for example he takes the general estimate of two and a half hours for a non trust impel it to reach the ileum which is defined in the patents into it as the lo evidence that this court in all the said is insufficient to establish infringement of an in people released limitation and the district court clearly erred in distinguishing although now in all of this court held there is no link between how long and how much drugs involved in a beaker and how long and how much drug is released in the body the same missing link also fatally in fact dr davis model he looked at how long and how much and then he asked an additional question which is where is the d form at that point the ultimate must be made first and as in all the it is not credible that such a link exists and that's particularly so in this case because there's even additional evidence that shows there's no link there's three seven is the beginning of it that forty nine ninety two is the conclusion that they reached there and they backed off of the twenty minutes just poster there was no kilometer absorption and the conclusion is on forty nine ninety two in summary two thousand we've got that troll and did your parents to confirm we only do things when the martin pressures us to do them and by the way the market had to pressure throughout that twenty five years but assuming your argument which is  be that it had been known since the one nine hundred fifty s that there's a motivation to drop down doses but the just generally can if that were the case every single extended release formulation would be non obvious and that's not the case here we know so much about trust b in the particular that for this particular drug why did the patent office do this then you're making it sound like they were course they had all this information in front of them they were just that testimony and credited it he did not reach the same conclusion that the prevailing sentiment in the arc would be demonstrated by the schroeder poster he had very specific reasons why he thought that the schroeder poster did not teach away from the claimed invention including the indicative of climate absorption particularly when you find nothing no information from the rectum if you put five know leaders in the rectum and you find that the blood levels go up that could be indicative of climate absorption but the opposite conclusion cannot be reached if you don't find any information from just just a tiny portion of the rectum of the very very very end of the colon they testified in the district judge her presumably credited that system but that conclusion cannot be reached from the other part of the record that i want to point out three seventy six i think your time's expired thank you thank  you for two minutes bickered rapidly first of all i'd like to address the peer reviewed paper that came from the poster and council comments that there was the backing off somehow in that there is on the very same page eight or nine nine two here's what they set that prolonged release preparation trusting fluorite due to the fact that has such poor absorption is lost for therapeutic effect they did not change as far as when this motivation took place this is the testimony of defendants  based on the benefit to the patient and i can't say why and then he says he can't see why matt out didn't do it and then i said so right now we're talking about as a nine hundred sixty seven shows being quite a bit on the market for twice a day yes yes and as of that time period wasn't done because he said tro t m is a very very poorly absorbed drug and that if you take it without any modification ninety percent of it's never going to get into the bloodstream dr to their experts at trosa and it's very challenging although x are is not a viable x are candidate and they expressed that skepticism so your honor asked was correct there is no answer for why so many five years went by others in the answers their own experts say which is trust b m is virtually impossible